Aod-9604

AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 from the C-terminal portion of human growth hormone, with an added tyrosine residue on the N-terminus. It is frequently sold in research-peptide channels under the name HGH Fragment 176-191, although that label technically refers to the same sequence without the extra tyrosine. The compound was designed to imitate growth hormone's lipolytic (fat-burning) activity while sidestepping the diabetes-promoting effects of full GH, supposedly working through beta-3 adrenergic receptors to break down fat and possibly aid cartilage regeneration. Like most peptides, it is sold as a research chemical that requires reconstitution and subcutaneous injection, so purity and storage matter.

Our editorial take is skeptical. The headline fact is hard to ignore: AOD-9604 failed phase II efficacy trials and was never approved, which is a strong signal that it does not deliver clinically meaningful fat loss. The evidence base earns only a C grade, weighted across 7 peer-reviewed studies (4 animal and 3 reviews), with 5 supporting and 2 mixed findings and zero human RCTs or meta-analyses on file. In other words, the supportive data come almost entirely from animals and review articles, not controlled human trials.

What the research actually shows is modest and conditional. In obese mice, AOD-9604 reduced body weight and fat by acting on beta-3 adrenergic receptors, but the effect vanished entirely in beta-3-AR knockout animals. A rabbit osteoarthritis study found that intra-articular AOD-9604 combined with hyaluronic acid produced the best reduction in cartilage degeneration, outperforming either treatment alone. A validated urine detection method identified a stable metabolite, and review articles list it among growth hormone fragments under investigation for obesity and orthopedic uses, while consistently noting that clinical evidence remains thin. A 2022 in vitro study even paired the fragment with doxorubicin-loaded nanoparticles against breast cancer cells, and a 1978 study showed related GH fragments could briefly raise blood glucose and reduce insulin sensitivity in rats.

Who should be cautious: realistically, anyone hoping this is a standalone fat-loss tool. Research indicates it only shows effects alongside calorie restriction, and the overwhelming majority of experienced users describe it as ineffective. Reviewers and users alike point toward full GH peptides, GLP-1 agonists such as semaglutide, tirzepatide, or retatrutide, or other proven compounds instead.

Community sentiment is lukewarm to negative. Across 137 community reports, roughly 26% were positive, 37% neutral, and 37% negative. The most commonly cited effect was weight loss, while reported downsides were mostly practical: the peptide is hydrophobic and prone to gelling or precipitating when reconstituted with standard bacteriostatic water.

On dosing, 0.25 mg daily is the figure most often mentioned. Studies ran 4-7 week protocols with weekly injections, suggesting any potential effect requires extended use. To avoid clumping, 0.6% acetic acid is recommended over plain bacteriostatic water, and administration is typically subcutaneous, though intra-articular injection has been studied for joint applications.

Availability is limited and contested. AOD-9604 can be obtained by prescription through 503A compounding pharmacies in the US, but the FDA voted against adding it to the list of bulk substances eligible for 503A compounding. It is also sold through various websites, where quality and legality vary by jurisdiction. Bottom line: the human efficacy data simply isn't there, and the hype outpaces the evidence.